Fisons Ltd.

Other

Thomas S Orr

David E Hall

Patrick John Kingsley

John Mann

Raymond W Keogh

There is described a pharmaceutical composition suitable for application to the skin and comprising, as active ingredient, a compound of formula I, ##STR1## in which R.sub.1 represents hydrogen, hydroxy or --NR.sub.5 R.sub.6, in which R.sub.5 and R.sub.6, which may be the same or different, each represent hydrogen or alkyl C 1 to 6,

Composition and method for treating skin mast cells and/or delayed

There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carb oxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention). There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Composition

A heartbeat rate monitor has a light source, powered by a rechargeable battery, for transilluminating skin tissue. A semiconductor detector which produces an output signal in dependence on light originating from the light source and reflected from the skin tissue, and hence on changes in arterial blood flow, is additionally used, on exposure to ambient light, to produce a current for recharging the battery.

Heartbeat rate monitor

Composition for treating skin mast cells and/or delayed cellular

There is described a pharmaceutical composition comprising one or more of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol; 5-(2-hydroxy-propoxy)-8-propyl-chromone-2-carboxylic acid; 6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-naphtho[2,3-b]pyran-2-carboxylic acid; 6,7,8,9-tetrahydro-5-hydroxy-4-oxo-10-propyl-4H-naphtho-[2,3-b]pyran-2-car boxylic acid; or a pharmaceutically acceptable salt of any one thereof, in combination with one or more of aspirin, indomethacin, phenylbutazone or oxyphenbutazone. (Mixtures of 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, with aspirin or indomethacin do not form part of the invention). There are also described packages containing the separate components of the composition and pharmaceutical formulations containing the composition.

Composition and methods of use

There is described a method of treatment of certain skin conditions, which method comprises per os administration of a compound of the formula I ##STR1## or a therapeutically acceptable salt, ester or amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, (as active ingredient), to a patient having such a condition.

Method for treatment of eczema or psoriasis

There is described a method of treatment of certain psychiatric conditions which method comprises administration of a compound of the formula I, ##STR1## or a therapeutically acceptacle salt, ester or amide thereof, (as active ingredient), to a patient having such a condition.

Method of psychiatric conditions

There is described a method of treatment of certain psychiatric conditions, or of certain skin conditions, which method comprises per os administration of a compound of the formula I ##STR1## or a therapeutically acceptable salt, ester or amide thereof, wherein X is a polymethylene chain containing 3 to 7 carbon atoms inclusive, which chain may be substituted by an --OH group, (as active ingredient), to a patient having such a condition.

Method of treating a psychiatric condition

There is described a pharmaceutical mixture comprising 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, and aspirin or indomethacin. The mixture causes less gastrointestinal adverse effects than aspirin or indomethacin on their own.

Growing community of inventors

Melton Mowbray, United Kingdom

Thomas S Orr